{
    "clinical_study": {
        "@rank": "31611", 
        "arm_group": {
            "arm_group_label": "Eribulin mesylate", 
            "arm_group_type": "Experimental", 
            "description": "Eribulin mesylate 1.4 mg/m2 IV bolus over 2-5 minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well eribulin mesylate works in treating patients with\n      advanced or recurrent cervical cancer. Drugs used in chemotherapy, such as eribulin\n      mesylate, work in different ways to stop the growth of tumor cells, either by killing the\n      cells or by stopping them from dividing"
        }, 
        "brief_title": "Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Recurrent Cervical Cancer", 
            "Stage IIIA Cervical Cancer", 
            "Stage IIIB Cervical Cancer", 
            "Stage IVA Cervical Cancer", 
            "Stage IVB Cervical Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate the activity of eribulin (eribulin mesylate) in the management of advanced or\n      recurrent cervical cancer (progression-free survival [PFS].\n\n      SECONDARY OBJECTIVES:\n\n      I. To describe the toxicity profile of eribulin in patients with advanced or recurrent\n      cervical cancer.\n\n      II. To estimate the survival of patients with advanced or recurrent cervical cancer treated\n      with eribulin.\n\n      III. To evaluate potential correlative studies as predictive or prognostic makers in this\n      patient population (glucose-regulated protein 78 [GRP78] levels in tissue and blood, tumor\n      protein p53 [p53] expression, apoptosis with terminal deoxynucleotidyl transferase dUTP nick\n      end labeling [TUNEL] assay, apoptosis-related proteins B-cell lymphoma 2 [Bcl-2] and\n      Bcl2-associated X protein [Bax] using immunohistochemistry [IHC], proliferation with Ki-67\n      IHC, and expression levels of microtubule-associated variables, including tau protein, total\n      alpha- and beta-tubulin, and classes II-IV beta-tubulin isotopes with IHC.\n\n      OUTLINE:  Patients receive eribulin mesylate 1.4 mg/m2 intravenously (IV) bolus over 2-5\n      minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression\n      or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up every 3 months for 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed diagnosis of invasive cervical cancer\n\n          -  Measurable disease\n\n          -  0-1 prior chemotherapy regimens for recurrent or advanced disease; platinum based\n             chemotherapy administered as a radiation sensitizer agent is allowed and does not\n             count as prior therapy\n\n          -  Absolute granulocyte count (AGC) >= 1,500\n\n          -  Platelet >= 100,000\n\n          -  Serum creatinine < 2.0 mg/dl\n\n          -  Bilirubin =< 1.5 times the upper limit of the normal range (ULN)\n\n          -  Alkaline phosphatase =< 3 x ULN (in the case of liver metastases, =< 5 x ULN)\n\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (in\n             the case of liver metastases, =< 5 x ULN)\n\n          -  Peripheral neuropathy grade 0-2\n\n          -  Recovery of all chemotherapy or radiation-related toxicities to grade =< 1, except\n             for alopecia and peripheral neuropathy\n\n          -  Performance status 0-2\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Prior treatment with eribulin\n\n          -  Chemotherapy, radiation, or biological or targeted therapy within 3 weeks\n\n          -  Hormonal therapy within 1 week\n\n          -  Any investigational drug within 4 weeks\n\n          -  Known brain metastases, unless previously treated and asymptomatic for 3 months and\n             not progressive in size or number for 3 months"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01676818", 
            "org_study_id": "5C-11-2", 
            "secondary_id": "NCI-2012-01378"
        }, 
        "intervention": {
            "arm_group_label": "Eribulin mesylate", 
            "description": "Given IV", 
            "intervention_name": "eribulin mesylate", 
            "intervention_type": "Drug", 
            "other_name": [
                "B1939", 
                "E7389", 
                "ER-086526", 
                "halichrondrin B analog"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "contact": {
                "email": "aagarcia@usc.edu", 
                "last_name": "Agustin A. Garcia", 
                "phone": "323-865-0451"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90033"
                }, 
                "name": "USC Norris Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Agustin A. Garcia", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Clinical Trial of Eribulin in Advanced or Recurrent Cervical Cancer", 
        "overall_official": {
            "affiliation": "University of Southern California", 
            "last_name": "Agustin Garcia", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Product limits estimates of 6-month PFS will be computed using all patients enrolled on the study. 95% confidence intervals will be based on Greenwood standard errors.", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "From the first day of treatment to the first observation of disease progression or death due to any cause, assessed at 6 months"
            }, 
            {
                "description": "The rate of grade 3+ hematologic and non-hematologic toxicities will be computed for course 1 and for all courses combined. Safety evaluation according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.3.", 
                "measure": "Number of participants with serious adverse events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01676818"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Exact 95% binomial confidence intervals will be computed for the BOR rate.  BOR defined as the best response recorded from the start of treatment until disease progression/recurrence, evaluated according to RECIST 1.1.", 
                "measure": "Best overall response (BOR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "From first day of treatment to time of death due to any cause, assessed up to 2 years"
            }
        ], 
        "source": "University of Southern California", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Southern California", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}